Publications by authors named "R Anty"
Background And Aims: Alcohol-related liver disease (ALD) is one of the leading causes of severe liver disease with limited pharmacological treatments for alcohol-related steatohepatitis (ASH). CD44, a glycoprotein mainly expressed in immune cells, has been implicated in multiple inflammatory diseases but has never been studied in the ALD context. We therefore studied its contribution to ASH development in mice and its expression in ALD patients.
View Article and Find Full Text PDFBackground & Aims: Current prognostic models for patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) are not extensively validated and widely accepted. We aimed to develop and validate a continuous model incorporating tumor burden and biology for individual survival prediction and risk stratification.
Methods: Overall, 4,377 treatment-naive candidates for whom TACE was recommended, from 39 centers in five countries, were enrolled and divided into training, internal validation, and two external validation datasets.
Article Synopsis
- - Metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent among obese individuals and shows differences between sexes. A study sought to create a noninvasive blood test using mid-infrared (MIR) metabolic fingerprinting to diagnose metabolic dysfunction-associated steatohepatitis (MASH) in those with severe obesity.
- - The study involved 382 patients undergoing bariatric surgery, with liver biopsies assessed to establish a scoring algorithm based on MIR spectroscopy. In women, MASH was diagnosed in 14.3% of cases, showing high sensitivity (86%) and specificity (81%) for correctly identifying the condition.
- - For men, the test's performance was notably less effective, with a MASH diagnosis
Background And Aims: The combination of atezolizumab plus bevacizumab (Atz/Bev) has radically changed the treatment strategy for advanced hepatocellular carcinoma (HCC) but raises questions. Our objectives were to determine survival outcomes and safety in a real-life multicenter French cohort, to investigate the on-treatment prognostic value of the bioinflammatory RECA score, and to perform a matched comparison with patients who previously received tyrosine kinase inhibitors (TKIs).
Methodology: A retrospective analysis of 109 consecutive patients enrolled from September 2020 to January 2023 and a post matched comparison with a TKI cohort ( n = 79) by the propensity score matching method.